Vectormune FP ILT + AE

ประเทศ: สหภาพยุโรป

ภาษา: โรมาเนีย

แหล่งที่มา: EMA (European Medicines Agency)

ซื้อเลย

สารออกฤทธิ์:

live recombinant fowlpox virus expressing the membrane fusion protein and the encapsidation protein of avian infectious laryngotracheitis virus (rFP-LT) and avian encephalomyelitis virus, strain Calnek 1143 (AE)

มีจำหน่ายจาก:

CEVA-Phylaxia Co. Ltd.

รหัส ATC:

Not assigned

INN (ชื่อสากล):

fowlpox, avian infectious laryngotracheitis vaccine (live, recombinant) and avian encephalomyelitis vaccine (live)

กลุ่มบำบัด:

Pui

พื้นที่บำบัด:

Immunologicals for aves, Live viral vaccines, Domestic fowl

ข้อบ่งชี้ในการรักษา:

For active immunisation of chickens of 8 to 13 weeks of age in order to reduce the skin lesions due to fowlpox, to reduce the clinical signs and tracheal lesions due to avian infectious laryngotracheitis and to prevent egg production losses due to avian encephalomyelitis.

สรุปสินค้า:

Revision: 1

สถานะการอนุญาต:

Autorizat

วันที่อนุญาต:

2020-04-24

แผ่นพับข้อมูลผู้ป่วย

                                B. PROSPECT
19
PROSPECT:
VECTORMUNE FP ILT + AE
LIOFILIZAT ȘI SOLVENT PENTRU SUSPENSIE INJECTABILĂ PENTRU PUI DE
GĂINĂ
1.
NUMELE ŞI ADRESA DEŢINĂTORULUI AUTORIZAŢIEI DE COMERCIALIZARE
ŞI A DEŢINĂTORULUI AUTORIZAŢIEI DE FABRICARE, RESPONSABIL PENTRU
ELIBERAREA SERIILOR DE PRODUS, DACĂ SUNT DIFERITE
Deținătorul autorizației de comercializare și producătorul
responsabil pentru eliberarea seriei:
Ceva-Phylaxia Co. Ltd.
1107 Budapesta, Szállás u. 5.
Ungaria
2.
DENUMIREA PRODUSULUI MEDICINAL VETERINAR
Vectormune FP ILT + AE liofilizat și solvent pentru suspensie
injectabilă pentru pui de găină
3.
DECLARAREA (SUBSTANŢEI) SUBSTANŢELOR ACTIVE ŞI A ALTOR
INGREDIENTE (INGREDIENŢI)
Fiecare doză (0,01 ml) conține:
SUBSTANȚE ACTIVE:
Virus viu recombinat al difterovariolei aviare care exprimă proteina
de fuziune membranară și
proteina de încapsidare a virusului laringotraheitei infecțioase
aviare (rFP-LT)
2.7 to 4.5 log10
TCID50*
Virusul encefalomielitei aviare, tulpina Calnek 1143 (AE)
2.7 to 4.5 log10 EID50**
* Doza infectanta 50 pe culturi celulare: titrul de virus necesar
pentru a produce infecție în 50% din
cultura tisulară inoculată
**Doza infectantă 50 pe ouă embrionate : titrul necesar pentru a
produce infecție în 50% din ouăle
inoculate
Liofilizat: alburiu-maroniu.
Solvent: lichid albastru, transparent.
4.
INDICAŢIE (INDICAŢII)
Pentru imunizarea activă a puilor de găină cu vârsta cuprinsă
între 8 și 13 săptămâni în scopul
reducerii leziunilor cutanate produse de difterovariolă, a reducerii
semnelor clinice și leziunilor
traheale produse de laringotraheita infecțioasă aviară și în
scopul prevenirii scăderii producției de ouă
datorită encefalomielitei aviare.
Instalarea imunității:
Difterovariolă și laringotraheită infecțioasă aviară: 3
săptămâni după vaccinare
Encefalomielita aviară: 20 săptămâni după vaccinare
Durata imunității:
Difterovariolă: 34 săptămâni după vaccinare.
Laringotraheita infecțioasă aviară și encefalomieli
                                
                                อ่านเอกสารฉบับเต็ม
                                
                            

สรุปลักษณะสินค้า

                                ANEXA I
REZUMATUL CARACTERISTICILOR PRODUSULUI
1
1.
DENUMIREA PRODUSULUI MEDICINAL VETERINAR
Vectormune FP ILT + AE liofilizat și solvent pentru suspensie
injectabilă pentru pui de găină
2.
COMPOZIŢIA CALITATIVĂ ŞI CANTITATIVĂ
Fiecare doză (0,01 ml) conține:
SUBSTANȚE ACTIVE:
Virus viu recombinat al difterovariolei aviare care exprimă proteina
de fuziune membranară și
proteina de încapsidare a virusului laringotraheitei infecțioase
aviare (rFP-LT)
2.7 to 4.5 log10
TCID50*
Virusul encefalomielitei aviare, tulpina Calnek 1143 (AE)
2.7 to 4.5 log10 EID50**
* Doza infectanta 50 pe culturi celulare: titrul de virus necesar
pentru a produce infecție în 50% din
cultura tisulară inoculată
**Doza infectantă 50 pe ouă embrionate : titrul necesar pentru a
produce infecție în 50% din ouăle
inoculate
Pentru lista completă a excipienților, vezi secțiunea 6.1.
3.
FORMA FARMACEUTICĂ
Liofilizat și solvent pentru suspensie injectabilă.
Liofilizat: alburiu-maroniu.
Solvent: lichid albastru, transparent.
4.
PARTICULARITĂŢI CLINICE
4.1
SPECII ȚINTĂ
Pui de găină
4.2
INDICAȚII PENTRU UTILIZARE, CU SPECIFICAREA SPECIILOR ȚINTĂ
Pentru imunizarea activă a puilor de găină cu vârsta cuprinsă
între 8 și 13 săptămâni în scopul
reducerii leziunilor cutanate produse de difterovariolă, a reducerii
semnelor clinice și leziunilor
traheale produse de laringotraheita infecțioasă aviară și în
scopul prevenirii scăderii producției de ouă
datorită encefalomielitei aviare.
Instalarea imunității:
Difterovariolă și laringotraheită infecțioasă aviară: 3
săptămâni după vaccinare
Encefalomielita aviară: 20 săptămâni după vaccinare
Durata imunității:
Difterovariolă: 34 săptămâni după vaccinare.
Laringotraheita infecțioasă aviară și encefalomielita aviară: 57
săptămâni după vaccinare.
4.3
CONTRAINDICAȚII
Nu sunt.
2
4.4
ATENȚIONĂRI SPECIALE PENTRU FIECARE SPECIE ȚINTĂ
Vaccinați doar animalele sănătoase.
4.5
PRECAUȚII SPECIALE PENTRU UTILIZARE
Precauții speci
                                
                                อ่านเอกสารฉบับเต็ม
                                
                            

เอกสารเป็นภาษาอื่น

แผ่นพับข้อมูลผู้ป่วย แผ่นพับข้อมูลผู้ป่วย บัลแกเรีย 09-09-2020
สรุปลักษณะสินค้า สรุปลักษณะสินค้า บัลแกเรีย 09-09-2020
สรุปลักษณะสินค้า สรุปลักษณะสินค้า เดนมาร์ก 09-09-2020
สรุปลักษณะสินค้า สรุปลักษณะสินค้า เยอรมัน 09-09-2020
แผ่นพับข้อมูลผู้ป่วย แผ่นพับข้อมูลผู้ป่วย เอสโตเนีย 09-09-2020
สรุปลักษณะสินค้า สรุปลักษณะสินค้า เอสโตเนีย 09-09-2020
สรุปลักษณะสินค้า สรุปลักษณะสินค้า อังกฤษ 09-09-2020
สรุปลักษณะสินค้า สรุปลักษณะสินค้า ฝรั่งเศส 09-09-2020
สรุปลักษณะสินค้า สรุปลักษณะสินค้า อิตาลี 09-09-2020
สรุปลักษณะสินค้า สรุปลักษณะสินค้า ลัตเวีย 09-09-2020
แผ่นพับข้อมูลผู้ป่วย แผ่นพับข้อมูลผู้ป่วย ลิทัวเนีย 09-09-2020
สรุปลักษณะสินค้า สรุปลักษณะสินค้า ลิทัวเนีย 09-09-2020
สรุปลักษณะสินค้า สรุปลักษณะสินค้า ฮังการี 09-09-2020
สรุปลักษณะสินค้า สรุปลักษณะสินค้า โปแลนด์ 09-09-2020
สรุปลักษณะสินค้า สรุปลักษณะสินค้า โปรตุเกส 09-09-2020
สรุปลักษณะสินค้า สรุปลักษณะสินค้า สโลวัก 09-09-2020
แผ่นพับข้อมูลผู้ป่วย แผ่นพับข้อมูลผู้ป่วย สโลวีเนีย 09-09-2020
สรุปลักษณะสินค้า สรุปลักษณะสินค้า สโลวีเนีย 09-09-2020
สรุปลักษณะสินค้า สรุปลักษณะสินค้า ฟินแลนด์ 09-09-2020
สรุปลักษณะสินค้า สรุปลักษณะสินค้า สวีเดน 09-09-2020
สรุปลักษณะสินค้า สรุปลักษณะสินค้า นอร์เวย์ 09-09-2020
แผ่นพับข้อมูลผู้ป่วย แผ่นพับข้อมูลผู้ป่วย ไอซ์แลนด์ 09-09-2020
สรุปลักษณะสินค้า สรุปลักษณะสินค้า ไอซ์แลนด์ 09-09-2020
แผ่นพับข้อมูลผู้ป่วย แผ่นพับข้อมูลผู้ป่วย โครเอเชีย 09-09-2020
สรุปลักษณะสินค้า สรุปลักษณะสินค้า โครเอเชีย 09-09-2020

ค้นหาการแจ้งเตือนที่เกี่ยวข้องกับผลิตภัณฑ์นี้

ดูประวัติเอกสาร